Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

A review of pomegranate in prostate cancer



Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials.


Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer (mCRPC).


In the BCR patient population, early phase II trials of both pomegranate juice and extract showed significant lengthening of PSA doubling time (PSADT), and confirmed the safety of pomegranate products. While a placebo-controlled phase III trial determined that pomegranate extract did not significantly prolong PSADT in BCR patients, a preplanned subset analysis of patients with the manganese superoxide dismutase (MnSOD) AA genotype showed greater PSADT lengthening on the pomegranate extract arm. In the neoadjuvant population, a large trial demonstrated a significant increase in urolithin A and a non-significant reduction in 8-hydroxy-2-deoxyguanosine, a marker of oxidation in prostate cancer tissue, on the pomegranate arm vs the placebo arm. In addition, a randomized clinical trial of a polyphenol-rich multicomponent food supplement that included a 31.25% pomegranate extract found significant slowing of PSA increase in the food supplement arm vs placebo in men on active surveillance and those experiencing BCR.


Pomegranate juice and extract are safe but did not significantly improve outcomes in BCR patients in a large placebo-controlled trial. However a subset of BCR patients with the MnSOD AA genotype appear to respond positively to the antioxidant effects of pomegranate treatment. Phase II trials of 100% pomegranate products in neoadjuvant patients and patients with mCRPC were negative. A multicomponent food supplement showed promising results in a phase II study in active surveillance and BCR patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others


  1. Freedland SJ, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y et al. A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. Cancer Prev Res 2013; 6: 1120–1127.

    Article  CAS  Google Scholar 

  2. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013; 16: 50–55.

    Article  CAS  PubMed  Google Scholar 

  3. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006; 12: 4018–4026.

    Article  CAS  PubMed  Google Scholar 

  4. Paur I, Lilleby W, Bohn SK, Hulander E, Klein W, Vlatkovic L et al. Tomato-based randomized controlled trial in prostate cancer patients: effect on PSA. Clin Nutr 2016; pii: S0261-5614(16)30147-9.

  5. Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T et al. Daily pomegranate intake has no impact on PSA levels in patients with advanced prostate cancer - results of a phase IIb randomized controlled trial. J Cancer 2013; 4: 597–605.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P . A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014; 17: 180–186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A et al. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis 2015; 18: 242–248.

    Article  CAS  PubMed  Google Scholar 

  8. Nutrition Business Journal. NBJ Supplement Business Report 2015. Penton Media, Inc.: 2015.

  9. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ . Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 2003; 103: 323–328.

    PubMed  Google Scholar 

  10. Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R . A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2003; 2: 212–216.

    Article  PubMed  Google Scholar 

  11. National Cancer Institute. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version. 2016. Available at:

  12. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA . Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 48: 4581–4589.

    Article  CAS  PubMed  Google Scholar 

  13. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H . Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 10350–10355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Saleem M, Adhami VM, Siddiqui IA, Mukhtar H . Tea beverage in chemoprevention of prostate cancer: a mini-review. Nutr Cancer 2003; 47: 13–23.

    Article  CAS  PubMed  Google Scholar 

  15. Aviram M, Dornfeld L . Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001; 158: 195–198.

    Article  CAS  PubMed  Google Scholar 

  16. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000; 71: 1062–1076.

    Article  CAS  PubMed  Google Scholar 

  17. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum for human breast cancer. Breast Cancer Res Treat 2002; 71: 203–217.

    Article  CAS  PubMed  Google Scholar 

  18. Artik N, Cemeroglu B, Murakami H, Mori T . Determination of phenolic compounds in pomegranate juice by HPLC. Fruit Process 1998; 8: 492–499.

    CAS  Google Scholar 

  19. Ben Nasr C, Ayed N, Metche M . Quantitative determination of the polyphenolic content of pomegranate peel. Z Lebensm Unters Forsch 1996; 203: 374–378.

    Article  CAS  PubMed  Google Scholar 

  20. Yang K, Lamprecht SA, Liu Y, Shinozaki H, Fan K, Leung D et al. Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis 2000; 21: 1655–1660.

    Article  CAS  PubMed  Google Scholar 

  21. Koide T, Kamei H, Hashimoto Y, Kojima T, Hasegawa M . Tannic acid raises survival rate of mice bearing syngeneic tumors. Cancer Biother Radiopharm 1999; 14: 231–234.

    Article  CAS  PubMed  Google Scholar 

  22. Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004; 7: 274–283.

    Article  CAS  PubMed  Google Scholar 

  23. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H . Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005; 102: 14813–14818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Malik A, Mukhtar H . Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006; 5: 371–373.

    Article  CAS  PubMed  Google Scholar 

  25. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther 2008; 7: 2662–2671.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005; 93: 1285–1294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F . Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004; 10: 8460–8464.

    Article  CAS  PubMed  Google Scholar 

  28. Wang Y, Zhang S, Iqbal S, Chen Z, Wang X, Wang YA et al. Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy. Prostate 2013; 74: 497–508.

    Article  Google Scholar 

  29. Gonzalez-Sarrias A, Gimenez-Bastida JA, Garcia-Conesa MT, Gomez-Sanchez MB, Garcia-Talavera NV, Gil-Izquierdo A et al. Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 2010; 54: 311–322.

    Article  CAS  PubMed  Google Scholar 

  30. Seeram NP, Zhang Y, McKeever R, Henning SM, Lee RP, Suchard MA et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 2008; 11: 390–394.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Pantuck AJ, Zomorodian N, Seeram N, Rettig M, Klatte T, Heber D et al Long Term Follow Up of Pomegranate Juice for Men with Prostate Cancer and Rising PSA Shows Durable Improvement in PSA Doubling Time. American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium: San Francisco, USA, 2008..

  32. Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA et al. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis 2013; 17: 28–33.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Iguchi T, Wang CY, Delongchamps NB, Kato M, Tamada S, Yamasaki T et al. Association of MnSOD AA genotype with the progression of prostate cancer. PLoS ONE 2015; 10: e0131325.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005; 65: 2498–2504.

    Article  CAS  PubMed  Google Scholar 

  35. So A . A Study of the Effectiveness of Pomegranate Pills in Men with Prostate Cancer before Prostatectomy. 2016. Available at:

  36. Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H . Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis 2012; 33: 644–651.

    Article  CAS  PubMed  Google Scholar 

  37. Physician PDQ Board. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Patient Version. 2 February 2017. Available at:

  38. Srinivas NR . Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence. Eur J Drug Metab Pharmacokinet 2013; 38: 223–229.

    Article  CAS  PubMed  Google Scholar 

  39. Abdlekawy KS, Donia AM, Elbarbry F . Effects of grapefruit and pomegranate juices on the pharmacokinetic properties of dapoxetine and midazolam in healthy subjects. Eur J Drug Metab Pharmacokinet 2016 (doi:10.1007/s13318-016-0352-3).

  40. Chan JM, Gann PH, Giovannucci EL . Role of diet in prostate cancer development and progression. J Clin Oncol 2005; 23: 8152–8160.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to C J Paller.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paller, C., Pantuck, A. & Carducci, M. A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis 20, 265–270 (2017).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links